Canada has bolstered its pandemic preparedness with a renewed contract with CSL Seqirus, a subsidiary of Australian biotechnology giant CSL Limited, to supply cell-based adjuvanted influenza vaccines. The agreement, announced on March 5, 2026, aims to protect Canadians in the event the World Health Organization (WHO) declares an influenza pandemic. This proactive step comes as influenza viruses with pandemic potential, including highly pathogenic avian influenza, continue to be detected in wild birds, poultry, and mammals globally, highlighting the ongoing threat of a widespread outbreak.
The contract signifies a shift in Canada’s pandemic strategy, moving from reliance on egg-based influenza vaccines to the more advanced cell-based technology. CSL Seqirus previously held a contract to provide egg-based vaccines, but this new agreement reflects the success of cell-based Flucelvax® in Canada’s seasonal influenza program over the past six years. The move to cell-based manufacturing offers several advantages, including scalability, reduced dependence on large volumes of critical materials, and the ability to rapidly produce vaccines using state-of-the-art technology, according to CSL Seqirus.
Advanced Manufacturing for Rapid Response
Under the terms of the contract, CSL Seqirus has committed to rapidly manufacture and deliver up to 15 million doses of cell-based adjuvanted influenza vaccines to Canada should the WHO declare a pandemic. This commitment builds on Canada’s existing robust pandemic preparedness plan, designed to ensure whole-population vaccine coverage if needed. The Australian-based company will leverage its advanced manufacturing capabilities to meet this demand, providing a critical layer of defense against a potential global health crisis.
“A flu pandemic is an ever-present threat,” said Gillian Stafford, Canadian Commercial Operations Director at CSL Seqirus, in a statement. The company’s expertise in vaccine development and manufacturing, combined with Canada’s established preparedness infrastructure, aims to provide a swift and effective response to a future pandemic.
CSL’s Global Role in Pandemic Preparedness
CSL Limited, established in 1916 as the Commonwealth Serum Laboratories, has evolved into a multinational specialty biotechnology company with a significant role in global health security. Originally wholly owned by the Australian federal government, CSL was privatized in 1994. Today, the company researches, develops, manufactures, and markets a diverse range of products, including blood plasma derivatives, vaccines, and antivenom. In 2024, CSL reported revenues of US$14.8 billion and net income of US$2.91 billion, employing approximately 32,000 people worldwide. CSL Limited’s website provides further information about the company’s operations and products.
Cell-Based Vaccines: A Technological Advancement
The shift towards cell-based vaccines represents a significant advancement in pandemic preparedness. Traditional egg-based vaccine production can be time-consuming and susceptible to issues like egg supply limitations and potential viral adaptation within the eggs. Cell-based manufacturing bypasses these challenges, offering a more reliable and scalable platform for rapid vaccine production. This technology allows for quicker adaptation to emerging viral strains and faster deployment of vaccines during a pandemic. The process also reduces reliance on critical materials, streamlining the supply chain and enhancing overall responsiveness.
Implications for Global Health Security
This contract between Canada and CSL Seqirus underscores the growing global focus on proactive pandemic preparedness. The COVID-19 pandemic highlighted the critical need for rapid vaccine development and manufacturing capabilities, and countries worldwide are investing in strengthening their defenses against future outbreaks. The collaboration between governments and private sector companies like CSL Seqirus is essential for ensuring a coordinated and effective response to emerging infectious disease threats. The agreement also demonstrates the importance of diversifying vaccine manufacturing capacity to reduce reliance on single sources and enhance global supply chain resilience.
The Canadian government’s investment in cell-based vaccine technology is a strategic move to enhance its ability to protect its population against future influenza pandemics. By securing a reliable supply of advanced vaccines, Canada is positioning itself to respond quickly and effectively to a potential global health crisis. This proactive approach is crucial for mitigating the impact of a pandemic and safeguarding public health.
The next step in this ongoing preparedness effort will be continued monitoring of global influenza activity and ongoing collaboration between CSL Seqirus and the Public Health Agency of Canada (PHAC) to refine pandemic response plans. Further details on Canada’s pandemic preparedness strategy can be found on the PHAC website.
This story is developing. Share your thoughts in the comments below.
